Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

Phase 2 Completed

97 enrolled 22 charts

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00494442 2018-08-01

ICEBERG 2

Phase 2 Completed

58 enrolled 13 charts

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT02340611 2018-06-12

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Phase 2 Completed

4 enrolled

Gynecologic

Ovarian Neoplasms

NCT01661868 2012-08-21

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Phase 2 Withdrawn

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

BOUQUET

DOVACC

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

BAROCCO

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

NEOCATS

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

STROBE

OCTOVA

NEO

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

OLAPem

MITO 31

Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

CONCERTO

DUETTE

ANLOLA

ICEBERG 3

ICEBERG 2

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer